Although TNF-alpha inhibitors remain the preferred choice for psoriatic arthritis (PsA) treatment following conventional DMARDs, the more recently introduced IL-17 inhibitors, Cosentyx and Taltz, and the oral therapies Otezla and Xeljanz have chipped away at the TNF inhibitors’ patient share. Understanding the unmet need in the treatment of PsA and the factors that can differentiate similar products from one another can determine the success of an agent in this competitive space. This report discusses the unmet needs associated with PsA treatment, based on the perceptions of U.S. and European rheumatologists, and which emerging therapies, if any, can capitalize on these opportunities.
- How do Novartis’s Cosentyx, Celgene’s Otezla, and Pfizer’s Xeljanz compare with the other agents used to treat PsA in terms of efficacy, safety, convenience of administration, and access to reimbursement?
- How do ACR response, PASI score, HAQ-DI improvement, risk of malignancy, and rate of infection affect rheumatologists’ prescribing decisions individually?
- How do U.S. and European rheumatologists view the value of oral therapies in treating PsA?
- What are the prevailing areas of unmet need and opportunity in the PsA therapy market?
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European rheumatologists fielded in February 2019
Key companies: AbbVie, Amgen, Janssen, Celgene, Novartis, Pfizer
Key drugs: Adalimumab, etanercept, infliximab, ustekinumab, apremilast, secukinumab, tofacitinib